ALZHEIMER’S ASSOCIATION WELCOMES U.S. FDA TRADITIONAL APPROVAL OF LEQEMBI: FULL DETAILS

CHICAGO, July 6, 2023 /PRNewswire/ — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to grant traditional approval of Leqembi™ (lecanemab, Eisai/Biogen) for the treatment of early Alzheimer’s disease with confirmation of elevated amyloid beta….